Grünenthal agreed to acquire the European rights (excluding Spain and the UK) to AstraZeneca’s Crestor (rosuvastatin) and its associated brands for a total consideration of up to $350 million.
AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
Healthy adults who do not keep their LDL-C, or “bad cholesterol,” in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.
Eisai Inc. announced positive top-line results from the CAMELLIA-TIMI 61 cardiovascular outcome trial.
Amgen announced that the New England Journal of Medicine published results from the Repatha (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).